The rise of quantum technology has opened the eyes of the ICT industry with respect to cryogenics. It is considered an enabler bringing in quantum functionalities and enhanced system performance and we are observing a massive growth of cryogenics from coolers to cryogenic electronics and photonics. ArCTIC is a joint effort of top European RTOs, industrial fabrication facilities, and leading application partners (23 industrial among which 14 SMEs, 7 RTO, 6 academic), sharing the vision to take a joint EU step towards the era of cryogenic classical and quantum microsystems. We aim to close the gap between qubit research and interfacing control machinery, highly needed for scaled-up quantum systems. The main goal of ArCTIC is to develop scalable cryogenic ICT microsystems and control technology for quantum processors. The technologies developed will have applications in many fields from sensing to communication, leading to important cross-fertilization that will strengthen the forming European ecosystem on cryogenic classical and quantum microsystems. ArCTIC will advance semiconductor technologies and materials, and tailor these for QT requirements and cryogenic applications. Multi-scale physics and data-driven models, cryogenic PDK modelling, device characterization, circuit design activities will support the development of cryogenic microelectronics. We will develop quantum processor platforms and broaden the applicability of microelectronic devices and circuits for cryogenic operation by developing cryo-compatible ultra-low loss substrates and thin-films, microelectronic and photonic circuits, semiconductor packaging and heterogeneous-integration techniques and benchmark the developed technologies. Scientific and Industrial ArCTIC-demonstrators and applications are driving our developments enabling the European industry to maintain and expand its leading edge in semiconductor components and processes and QT and strengthen sustainable manufacturing technologies

The ambition of PRYSTINE is to strengthen and to extend traditional core competencies of the European industry, research and universities in smart mobility and in particular the electronic component and systems and cyber-physical systems domains. PRYSTINE's target is to realize Fail-operational Urban Surround perceptION (FUSION) which is based on robust Radar and LiDAR sensor fusion and control functions in order to enable safe automated driving in urban and rural environments. Therefore, PRYSTINE's high-level goals are: 1. Enhanced reliability and performance, reduced cost and power of FUSION components 2. Dependable embedded control by co-integration of signal processing and AI approaches for FUSION 3. Optimized E/E architecture enabling FUSION-based automated vehicles 4. Fail-operational systems for urban and rural environments based on FUSION PRYSTINE will deliver (a) fail-operational sensor-fusion framework on component level, (b) dependable embedded E/E architectures, and (c) safety compliant integration of Artificial Intelligence (AI) approaches for object recognition, scene understanding, and decision making within automotive applications. The resulting reference FUSION hardware/software architectures and reliable components for autonomous systems will be validated in in 22 industrial demonstrators, such as: 1. Fail-operational autonomous driving platform 2. An electrical and highly automated commercial truck equipped with new FUSION components (such as LiDAR, Radar, camera systems, safety controllers) for advanced perception 3. Highly connected passenger car anticipating traffic situations 4. Sensor fusion in human-machine interfaces for fail-operational control transition in highly automated vehicles PRYSTINE’s well-balanced, value chain oriented consortium, is composed of 60 project partners from 14 different European and non-European countries, including leading automotive OEMs, semiconductor companies, technology partners, and research institutes.

The objective of POSITION-II is to bring innovation in the development and production of smart catheters by the introduction of open technology platforms for miniaturization, AD conversion at the tip, ultra-sound MEMS devices and encapsulation. Open technology platforms will generate the production volume that will enable sustainable innovation. The availability of open technology platforms will result in new instruments that have a better performance, new sensing and imaging capabilities, while the scale of volume will result in lower manufacturing costs. The production of the “brains” of these smart catheters will take place in Europe, with many European partners contributing essential technologies. The POSITION-II project will consolidate Europe’s premier position as manufacturer of cath lab infrastructure since these new smart catheters will be seamlessly integrated in the cath lab hardware and software platforms. By combining the different sensing and imaging data a more intuitive cath lab experience will be achieved. Looking forward, POSITION-II prepares the European electronics industry for the next revolution in healthcare, bioelectronics implants. Bioelectronics implants are expected to replace a considerable fraction of traditional medicine by direct stimulation of nerves. The miniaturization and soft encapsulation platforms developed in POSITION-II will be the ideal technology frame work for the manufacturing of these bioelectronics implants. The technology platforms developed in POSITION-II are demonstrated by five challenging product demonstrators covering FRR, IVUS, ICE, EP and cell therapy as well as a bioelectronics implant to treat cluster headache.

Compared to the pace of innovation in electronic consumer products, the pace of innovation for medical devices is lagging behind. It is the overarching objective of Moore4Medical to accelerate innovation in electronic medical devices. Moore4Medical emerging medical applications that offer significant new opportunities for the ECS industry including: active implantable devices (bioelectronic medicines), organ-on-chip, drug adherence monitoring, smart ultrasound, radiation free interventions and continuous monitoring. The new technologies will help fighting the increasing cost of healthcare by: reducing the need for hospitalization, helping the development of personalized therapies, and realizing intelligent point-of-care diagnostic tools. Moore4Medical will bring together 68 specialists from 12 countries who will develop open technology platforms for these emerging fields to help them bridge “the Valley of Death” in shorter time and at lower cost. Open technology platforms used by multiple users for multiple applications with the prospect of medium to high volume markets are an attractive proposition for the European ECS industry. The combination of typical MedTech applications with an ECS style platform approach will enhance the competitiveness for the emerging medical domains addressed in Moore4Medical. With value and IP moving from the technology level towards applications and solutions, defragmentation and open technology platforms will be key in acquiring and maintaining a premier position for Europe in the forefront of affordable healthcare